rozrolimupab

also known as SYM-001

Monoclonal antibody targets RHD via inhibition

today NCT00718692 · Ph 2

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00718692	Jul 2008 → Aug 2011	autoimmune thrombocytopenic purpura	Symphogen A/S	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	rozrolimupab	“Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures.” PMID 22915649 ↗ Aug 2012
Known as	SYM-001	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107859 ↗
Action	Inhibit	“Blood group Rh(D) polypeptide inhibitor” CHEMBL2107859 ↗
Modality	Monoclonal antibody	“Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures.” PMID 22915649 ↗ Aug 2012
Target	RHD	“Blood group Rh(D) polypeptide inhibitor” CHEMBL2107859 ↗